ASH 2016 - Multiple Myeloma

Tiffany Richards shares anecdotes that illustrate why it's important to really know your patients in order to effectively care for them.
Beth Faiman reflects on the considerations involved with managing patients who have experienced multiple myeloma relapses.
Leslie Lauersdorf explains why it's so important to understand the patient's baseline to help manage side effects.
Tiffany Richards discusses the numerous, often unmet, needs of patients with multiple myeloma.
Researchers conducted a systematic literature review and subsequent meta-analysis of progression-free survival outcomes to compare 16 different treatment regimens for relapsed/refractory multiple myeloma.
Outcomes of patients with relapsed/refractory multiple myeloma are poor, but are improving as treatment options expand.
Leslie Lauersdorf is excited by the prospect of new mutliple myeloma therapies, and notes that finding the best sequence for each patient is key.
Leslie Lauersdorf believes patient education is important in both newly diagnosed pateints with multiple myeloma or patients with relapsed/refractory disease to help them understand their disease and the different treatment options.
Beth Faiman sees daratumumab as a game changer for patients with multiple myeloma.
Preliminary data suggest that subcutaneous delivery of daratumumab in patients with relapsed/refractory multiple myeloma is well-tolerated and yields similar response rates to intravenous administration of the drug.
Page 3 of 6
Results 21 - 30 of 51